[Skip to Navigation]
Views 984
Citations 0
Comment & Response
April 28, 2021

Statin Prescribing and Dosing—Failure Has Become an Option—Reply

Author Affiliations
  • 1Penn Medicine Nudge Unit, University of Pennsylvania, Philadelphia, Pennsylvania
  • 2Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 3Office of the Chief Medical Information Officer, University of Pennsylvania Health System, Philadelphia
  • 4Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania
  • 5The Wharton School, University of Pennsylvania, Philadelphia
JAMA Cardiol. 2021;6(7):855. doi:10.1001/jamacardio.2021.0838

In Reply We thank Mark et al for their comments regarding our work on statin prescription decision support embedded within the electronic health record.1 We appreciate their interest and the perspective they have added, particularly regarding the important topic of statin intolerance and resistance.

We agree that the evidence base for the prescription of statin therapy for primary and secondary prevention of cardiovascular disease is robust, as is the one illustrating gaps and inequities in guideline-directed statin prescription.2 These gaps can also be exacerbated by the cognitive constraints, biases, and motivation of health care professionals and patients, even throughout the same clinic day, as exemplified by a decrease in new statin prescriptions as a clinic day progresses.3 This calls for the creation, testing, and implementation of multifaceted clinician-focused, patient-focused, and system-focused behavioral strategies aimed at overcoming inertia to initiating and maintaining statin therapy in appropriate patients.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words